Your browser doesn't support javascript.
loading
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.
Gan, Li-Ming; Lagerström-Fermér, Maria; Carlsson, Leif G; Arfvidsson, Cecilia; Egnell, Ann-Charlotte; Rudvik, Anna; Kjaer, Magnus; Collén, Anna; Thompson, James D; Joyal, John; Chialda, Ligia; Koernicke, Thomas; Fuhr, Rainard; Chien, Kenneth R; Fritsche-Danielson, Regina.
Afiliación
  • Gan LM; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden. li-ming.gan@astrazeneca.com.
  • Lagerström-Fermér M; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Arvid Wallgrens backe 1, 413 46, Gothenburg, Sweden. li-ming.gan@astrazeneca.com.
  • Carlsson LG; Department of Cardiology, Sahlgrenska University Hospital, Blå stråket 5, 413 45, Gothenburg, Sweden. li-ming.gan@astrazeneca.com.
  • Arfvidsson C; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Egnell AC; Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Rudvik A; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Kjaer M; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Collén A; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Thompson JD; Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Joyal J; Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, 431 50, Mölndal, Sweden.
  • Chialda L; Moderna, Inc., 200 Technology Square, Cambridge, MA, 02139, USA.
  • Koernicke T; Moderna, Inc., 200 Technology Square, Cambridge, MA, 02139, USA.
  • Fuhr R; PAREXEL Early Phase Clinical Unit, Westend Clinic, House 31, 14050, Berlin, Germany.
  • Chien KR; PAREXEL Early Phase Clinical Unit, Westend Clinic, House 31, 14050, Berlin, Germany.
  • Fritsche-Danielson R; PAREXEL Early Phase Clinical Unit, Westend Clinic, House 31, 14050, Berlin, Germany.
Nat Commun ; 10(1): 871, 2019 02 20.
Article en En | MEDLINE | ID: mdl-30787295
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piel / ARN Mensajero / Neovascularización Fisiológica / Factor A de Crecimiento Endotelial Vascular / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piel / ARN Mensajero / Neovascularización Fisiológica / Factor A de Crecimiento Endotelial Vascular / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Suecia